Download PDF
Digestive Disease Interventions 2021; 05(02): 118-122
DOI: 10.1055/s-0041-1729875
Review Article

Radioembolization for Rare Metastatic Disease

Andrew S. Niekamp
1   Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Miami, Florida
,
Govindarajan Narayanan
1   Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Miami, Florida
,
Brian J. Schiro
1   Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Miami, Florida
,
Constantino Pena
1   Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Miami, Florida
,
Alex Powell
1   Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Miami, Florida
,
Ripal T. Gandhi
1   Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Miami, Florida
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Radioembolization has become a widespread treatment modality for both primary and metastatic hepatic malignancies. Although the majority of data and indication for yttrium-90 radioembolization have been for hepatocellular carcinoma and metastatic colorectal cancer, radioembolization with yttrium-90 has rapidly expanded into the treatment options for multiple tumor types with metastases to the liver. This article reviews the clinical data and expanding utilization of radioembolization for rare metastatic diseases with an emphasis on efficacy and safety.

Keywords

radioembolization - rare metastatic diseases - malignancy

Financial Disclosure

A.S.N.: nothing to disclose; G.N.: consultant (Angiodynamics, Boston Scientific, Guerbet, Incyte); B.J.S.: speaker (SIRTEX, Penumbra); C.P.: consultant (Boston Scientific, SIRTEX); A.P.: speaker (Penumbra, Bard); R.T.G.: consultant (SIRTEX).




Publication History

Received: 07 December 2020

Accepted: 05 March 2021

Article published online:
20 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Khajornjiraphan N, Thu NA, Chow PK. Yttrium-90 microspheres: a review of its emerging clinical indications. Liver Cancer 2015; 4 (01) 6-15
    CrossrefPubMedGoogle Scholar
  • 2 American Cancer Society. Cancer Statistics Center. Accessed November 3, 2020 at: http://cancerstatisticscenter.cancer.org
    PubMedGoogle Scholar
  • 3 Zaheer QA, Sherry R, Sharmi B, Sri Lekha B, Stacey TE, Faryal A. Pancreatic cancer with metastasis to liver: report of a case. Am J Gastroenterol 2018; 113: S1607-S1608
    CrossrefPubMedGoogle Scholar
  • 4 Ouyang H, Wang P, Meng Z. et al. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 2011; 40 (01) 120-125
    CrossrefPubMedGoogle Scholar
  • 5 Gulec SA, Wheeler J, Pennington K. et al. Chemotherapy with yttrium-90 microsphere selective internal radiation treatment and selective external radiation treatment in patients with metastatic pancreatic cancer. J Interv Oncol 2009; 2 (01) 84-92
    PubMedGoogle Scholar
  • 6 Michl M, Haug AR, Jakobs TF. et al. Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology 2014; 86 (01) 24-32
    CrossrefPubMedGoogle Scholar
  • 7 Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcinoma: a single center experience. BMC Cancer 2016; 16: 492
    CrossrefPubMedGoogle Scholar
  • 8 Kim AY, Frantz S, Brower J, Akhter N. Radioembolization with yttrium-90 microspheres for the treatment of liver metastases of pancreatic adenocarcinoma: a multicenter analysis. J Vasc Interv Radiol 2019; 30 (03) 298-304.e2
    CrossrefPubMedGoogle Scholar
  • 9 Bailey RE, Surapaneni PK, Core J. et al. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. J Gastrointest Oncol 2019; 10 (04) 688-694
    CrossrefPubMedGoogle Scholar
  • 10 Kayaleh R, Krzyston H, Rishi A. et al. Transarterial radioembolization treatment of pancreatic cancer patients with liver-dominant metastatic disease using yttrium-90 glass microspheres: a single-institution retrospective study. J Vasc Interv Radiol 2020; 31 (07) 1060-1068
    CrossrefPubMedGoogle Scholar
  • 11 Gibbs P, Do C, Lipton L. et al. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer 2015; 15: 802
    CrossrefPubMedGoogle Scholar
  • 12 Nezami N, Camacho JC, Kokabi N, El-Rayes BF, Kim HS. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin. J Gastrointest Oncol 2019; 10 (05) 944-956
    CrossrefPubMedGoogle Scholar
  • 13 Devulapalli KK, Fidelman N, Soulen MC. et al. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology 2018; 288 (03) 774-781
    CrossrefPubMedGoogle Scholar
  • 14 Kennedy A, Brown DB, Feilchenfeldt J. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017; 8 (06) 1079-1099
    CrossrefPubMedGoogle Scholar
  • 15 Seedor RS, Eschelman DJ, Gonsalves CF. et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12 (01) 117
    CrossrefPubMedGoogle Scholar
  • 16 Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford) 2020; 22 (04) 497-505
    CrossrefPubMedGoogle Scholar
  • 17 Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011; 196 (02) 468-473 DOI: 10.2214/AJR.10.4881.
    CrossrefPubMedGoogle Scholar
  • 18 Kennedy AS, Nutting C, Jakobs T. et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27 (06) 682-690
    CrossrefPubMedGoogle Scholar
  • 19 Eldredge-Hindy H, Ohri N, Anne PR. et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. Am J Clin Oncol 2016; 39 (02) 189-195
    CrossrefPubMedGoogle Scholar
  • 20 Levey AO, Elsayed M, Lawson DH. et al. Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization. Cardiovasc Intervent Radiol 2020; 43 (02) 254-263
    CrossrefPubMedGoogle Scholar
  • 21 Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. J Vasc Interv Radiol 2018; 29 (10) 1369-1375
    CrossrefPubMedGoogle Scholar
  • 22 Ponti A, Denys A, Digklia A. et al. First-line selective internal radiation therapy in patient with uveal melanoma liver metastases. J Nucl Med 2020; 61 (03) 350-356
    CrossrefPubMedGoogle Scholar
  • 23 Schelhorn J, Richly H, Ruhlmann M, Lauenstein TC, Theysohn JM. A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol Open 2015; 4 (04) 2047981615570417
    PubMedGoogle Scholar
  • 24 Gonsalves CF, Eschelman DJ, Adamo RD. et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 2019; 293 (01) 223-231
    CrossrefPubMedGoogle Scholar
  • 25 Abbott AM, Doepker MP, Kim Y. et al. Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol 2018; 41 (08) 747-753
    CrossrefPubMedGoogle Scholar
  • 26 Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221 (04) 392-397
    CrossrefPubMedGoogle Scholar
  • 27 Transue DL, Hackworth J, Johnson MS. et al. Multi-institutional experience treating metastatic soft tissue sarcomas using yttrium-90 microspheres. J Vasc Interv Radiol 2015; 26 (2, Suppl): S133, Abstract 290
    CrossrefPubMedGoogle Scholar
  • 28 Mauro D, Kim E, Tabori N. et al. Hepatic radioembolization for treatment of metastatic sarcoma as salvage therapy after failed chemotherapy: single center midterm results. J Vasc Interv Radiol 2016; 27 (3, Suppl): S154-S155, Abstract 341
    CrossrefPubMedGoogle Scholar
  • 29 Miller MD, Sze DY, Padia SA. et al. Response and overall survival for yttrium-90 radioembolization of hepatic sarcoma: a multicenter retrospective study. J Vasc Interv Radiol 2018; 29 (06) 867-873
    CrossrefPubMedGoogle Scholar
  • 30 Pierce DB, Johnson GE, Monroe E. et al. Safety and efficacy outcomes of embolization in hepatic sarcomas. AJR Am J Roentgenol 2018; 210 (01) 175-182
    CrossrefPubMedGoogle Scholar
  • 31 Ruohoniemi DM, Zhan C, Wei J. et al. Safety and effectiveness of yttrium-90 radioembolization around the time of immune checkpoint inhibitors for unresectable hepatic metastases. J Vasc Interv Radiol 2020; 31 (08) 1233-1241
    CrossrefPubMedGoogle Scholar
  • 32 Burnett NP, Akinwande O, Scoggins CR. et al. Comparison of yttrium-90 therapy for unresectable liver metastasis: glass versus biocompatible resin microspheres. J Radiat Oncol 2017; 6: 101-108
    CrossrefPubMedGoogle Scholar
  • 33 Demirelli S, Erkilic M, Oner AO. et al. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Nucl Med Commun 2015; 36 (04) 340-349
    CrossrefPubMedGoogle Scholar
  • 34 Yttrium 90 resin microspheres data collection in unresectable liver cancer: the RESIN Study (RESiN). Accessed November 12, 2020 at: https://clinicaltrials.gov/ct2/show/NCT02685631
    PubMedGoogle Scholar